"Cyclohexanols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.
| Descriptor ID |
D003511
|
| MeSH Number(s) |
D02.033.415.510.500 D02.455.426.392.368.367.318 D10.289.510.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclohexanols".
Below are MeSH descriptors whose meaning is more specific than "Cyclohexanols".
This graph shows the total number of publications written about "Cyclohexanols" by people in this website by year, and whether "Cyclohexanols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclohexanols" by people in Profiles.
-
Does cognitive-behavioral therapy response in youth with obsessive-compulsive disorder differ if treatment ends during summer? Ann Clin Psychiatry. 2014 Nov; 26(4):299-300.
-
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer. 2015 Feb; 23(2):513-24.
-
The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders. Behav Res Ther. 2013 Nov; 51(11):729-35.
-
The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Hum Psychopharmacol. 2009 Jun; 24(4):331-6.
-
Differences between daily smokers, chippers, and nonsmokers with co-occurring anxiety and alcohol-use disorders. Addict Behav. 2008 Nov; 33(11):1425-1431.
-
The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. Pharmacogenomics J. 2007 Aug; 7(4):266-74.
-
Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp Clin Psychopharmacol. 2005 Nov; 13(4):282-92.
-
Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder. Psychoneuroendocrinology. 2006 Apr; 31(3):355-60.
-
The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res. 2004 Apr; 6(2):229-39.
-
Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003 Nov; 37(11):1561-5.